title: Brentuximab vedotin for treating Hodgkin's lymphoma: an analysis of pharmacology and clinical efficacy.
abstract: BACKGROUND
  Hodgkin's lymphoma (HL) is a highly curable lymphoma with a 70 - 90% long-term survival; however, patients with relapsed or refractory disease may need additonal therapies and have significantly worse prognosis. Brentuximab vedotin (BV) is an anti-CD-30 antibody-drug conjugate, which was approved for treating classical HL patients following autologous stem cell transplantation or failure of at least two prior multi-agent chemotherapies within a year.
  
  
  METHODS
  Current clinical trials are investigating the role of BV in frontline, salvage and adjuvant setting of treatment. Safety and efficacy results of completed trials are summarized in this review. Metabolic, pharmacokinetic issues of BV are also discussed.
  
  
  CONCLUSIONS
  BV is a targeted therapeutic option for treating HL, which is a significant improvement compared to conventional multiagent chemotherapy. It may represent a valid option for heavily pretreated patients. Currently running clinical trials are seeking a role for BV in the first-line setting, as well as treating autologous stem cell transplant candidate patients, relapsing after autologous stem cell transplant, bridging to allogenic stem cell transplant and treating elderly patients. Indication of drug may change, expand and an exact role may be established in the upcoming 5 years based on the results of currently running trials.
authors: University of Debrecen, Institution of Internal Medicine, Department of Hematology, Faculty of Medicine , Debrecen , Hungary.
authors: Árpád
authors: Á
authors: Illés
authors: Ádám
authors: Á
authors: Jóna
authors: Zsófia
authors: Z
authors: Miltényi
mesh_terms: D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D000079963:Brentuximab Vedotin; D006689:Hodgkin Disease / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy; D033581:Stem Cell Transplantation / Q000379:methods; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin
keywords: Hodgkin lymphoma; brentuximab vedotin; cytotoxic effect; monomethylauristatin E; refractory; relapse; stem cell transplantation